TATVA — Tatva Chintan Pharma Chem Income Statement

0.000.00%

Last trade - 00:00

Basic MaterialsBalancedSmall CapNeutral

Annual income statement for Tatva Chintan Pharma Chem, fiscal year end - March 31st, INR millions except per share, conversion factor applied.

	2020 March 31st	C2021 March 31st	2022 March 31st	2023 March 31st	2024 March 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	PROSPECTUS	ARS	ARS	ARS	ARS
Standards:	IAS	IAS	IAS	IAS	IAS
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	2,632	3,004	4,336	4,236	3,935
Cost of Revenue
Gross Profit	1,215	1,321	2,034	1,654	1,753
Selling / General / Administrative Expenses
Research And Development
Depreciation and Amortization
Other Operating Expenses
Total Operating Expenses	2,109	2,406	3,335	3,653	3,498
Operating Profit	524	598	1,002	583	437
Gain / Loss on Sale of Assets
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes	476	607	1,041	448	436
Provision for Income Taxes
Net Income After Taxes	378	523	959	455	304
Net Income Before Extraordinary Items
Net Income	378	523	959	455	304
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Diluted Net Income	378	523	959	455	304
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	17.1	23.6	44.6	21.6	13.3
Dividends per Share